This substudy of the DanGer Shock trial assessed outcomes associated with the use of Impella CP® for the management of cardiogenic shock (CS) secondary to myocardial infarction (MI) according to patient age.
This state-of-the-art document provides an overview of current donor selection strategies in heart transplantation (HT), highlighting how technical advances have enabled an expansion in the donor pool and increased transplant rates.
4th report of the EUROMACS registry by the EACTS with a focus on standardized outcome ratios
Systematic review of observational studies and case series evaluating the use of the Impella® device as hemodynamic support prior to definitive treatment in patients with post-infarction ventricular septal defect (VSD).
A retrospective study analyzing the relationship between the donor-to-recipient right ventricular mass (RVM) ratio and the recipient’s pre-transplant pulmonary vascular resistance (PVR), proposing that PVR may influence the effect of this RVM ratio on post-transplant outcomes.
Update on organizational and care aspects in the management of patients with advanced heart failure
A prospective, multicenter study on the implantation of the HeartMate 3® device via thoracotomy, evaluating the safety and efficacy of this approach.
The DanGer Shock clinical trial substudy analyzes the relationship between the use of the microaxial flow pump (Impella CP®) and renal dysfunction in patients with cardiogenic shock secondary to myocardial infarction.
Introduction and Update on Clinical Experience with Impella 5.5 at the Hospital Universitari i Politècnic La Fe
A single-center retrospective study analyzing a case series over four years involving patients who underwent valve replacement surgery and required veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in the immediate postoperative period.
If you wish to receive our monthly newsletter, containing all the news collected on our portal, please fill in your email address and click on the “Subscribe” button.